Rifkin A, Quitkin F, Kane J, Struve F, Klein D F
Arch Gen Psychiatry. 1978 Apr;35(4):483-9. doi: 10.1001/archpsyc.1978.01770280093010.
Of 55 aftercare patients receiving long-term treatment with antipsychotic and antiparkinson (AP) drugs, 37 were switched to being given placebo, and 18 remained on a regimen of procyclidine hydrochloride. The dose of antipsychotic was kept constant. After three weeks extrapyramidal side effects (EPS) developed in 54% of those patients receiving placebo and in none of those receiving procyclidine (P less than .002): Twenty-seven percent of the placebo group had EPS without akinesia, and in the same percentage akinesia developed (P = .003). We believe the risk-benefit ratio favors the routine use of AP drugs for prophylaxis and maintenance so as to avoid misdiagnosing as psychopathology, unspontaneity due to akinesia, and to reduce unreliable pill-taking due to EPS.
在55名接受抗精神病药物和抗帕金森病（AP）药物长期治疗的后续护理患者中，37名患者改用安慰剂，18名患者继续服用盐酸丙环定。抗精神病药物的剂量保持不变。三周后，接受安慰剂的患者中有54%出现锥体外系副作用（EPS），而接受丙环定的患者中无一出现（P<0.002）：安慰剂组中27%的患者出现无运动不能的EPS，相同比例的患者出现运动不能（P = 0.003）。我们认为，风险效益比有利于常规使用AP药物进行预防和维持治疗，以避免误诊为精神病理学、因运动不能导致的不自主以及减少因EPS导致的服药不可靠。
